PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) has updated its requirements for risk management plans to be submitted with applications for new drugs and biologics.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) has updated its requirements for risk management plans to be submitted with applications for new drugs and biologics.
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease.
PERTH, Australia – The Australian government's commitment of more than AU$1 billion (US$711 million) to support medical research in cancer and genomics sends the message to investors that the life sciences sector in Australia is sustainable, stakeholders said.
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease.
